| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -27,947 | -22,816 |
| Stock-based compensation expense | 9,180 | 9,071 |
| Depreciation and amortization expenses | 615 | 409 |
| Prepaid expenses and other current assets | -627 | -501 |
| Accounts payable and accrued expenses | -1,343 | 147 |
| Operating lease liabilities | -423 | -278 |
| Net cash used in operating activities | -19,291 | -12,966 |
| Purchase of property and equipment | - | 0 |
| Net cash used in investing activities | - | 0 |
| Proceeds from the exercise of stock options | - | 0 |
| Sales of shares of common stock, net of costs | - | 0 |
| Payments on finance leases | 7 | 5 |
| Restricted stock units withheld to cover tax obligations | 207 | - |
| Net cash used in/provided by financing activities | -214 | -5 |
| Net change in cash, cash equivalents, and restricted cash | -19,505 | -12,971 |
| Cash and cash equivalents at beginning of period | 73,228 | - |
| Cash and cash equivalents at end of period | 53,723 | - |
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)